Hostname: page-component-848d4c4894-nmvwc Total loading time: 0 Render date: 2024-06-13T13:27:22.739Z Has data issue: false hasContentIssue false
  • English
  • Français

The novel antipsychotic cariprazine (RGH-188): State-of-the-art in the treatment of psychiatric disorders

Published online by Cambridge University Press:  23 March 2020

L. Orsolini ,
A. Valchera ,
D. De Berardis ,
R. Vecchiotti  and
F. Iasevoli
L. Orsolini*
Affiliation:
Villa San Giuseppe Hospital, Hermanas Hospitalarias, Department of Psychiatry, Ascoli Piceno, Italy Maastricht University, Department of Psychiatry and Neuropsychology, Maastricht, Italy University of Hertfordshire, Department of Pharmacy, School of Life and Medical Sciences, Hatfield, United Kingdom Polyedra, Polyedra Research, Teramo, Italy
A. Valchera
Affiliation:
Polyedra, Polyedra Research, Teramo, Italy Villa San Giuseppe Hospital, Heramanas Hospitalarias, Department of Psychiatry, Ascoli Piceno, Italy
D. De Berardis
Affiliation:
Polyedra, Polyedra Research, Teramo, Italy Hospital “G. Mazzini”, ASL 4, NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Teramo, Italy University of “G. D’Annunzio”, Department of Neuroscience, Imaging and Clinical Science, Chieti, Italy
R. Vecchiotti
Affiliation:
Villa San Giuseppe Hospital, Hermanas Hospitalarias, Department of Psychiatry, Ascoli Piceno, Italy Maastricht University, Department of Psychiatry and Neuropsychology, Maastricht, Italy Polyedra, Polyedra Research, Teramo, Italy
F. Iasevoli
Affiliation:
Laboratory of Molecular Psychiatry and Psychopharmacotherapeutics, Section of Psychiatry, Department of Neuroscience, University School of Medicine “Federico II”, Naples, Italy
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Cariprazine (RGH-188) is a novel antipsychotic drug that exerts partial agonism of dopamine D2/D3 receptors with preferential binding to D3 receptor, antagonism of 5HT2B receptors and partial agonism of 5HT1A. Currently, cariprazine is in late-stage clinical development (phase III clinical trials) in patients with schizophrenia (S) and in patients with bipolar disorder (BD), as well as an adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD.

Objectives

Cariprazine has completed phase III trials for the acute treatment of schizophrenia and bipolar mania, phase II trials for the bipolar depression and MDD whilst it is undergoing phase III trials as an adjunct to antidepressants.

Aims

The present review aims at proving a comprehensive summary of the current evidence on the safety, tolerability and efficacy of cariprazine in the treatment of schizophrenia, BD (manic/mixed/depressive episode) and MDD.

Methods

A systematic search was conducted on PubMed/Medline/Scopus and the database on Clinical Trials from inception until April 2015 by typing a set of specified keywords.

Results

Available evidence seems to support cariprazine efficacy in the treatment of cognitive and negative symptoms of schizophrenia. Preliminary findings suggest its antimanic activity whilst it is still under investigation its efficacy in the treatment of bipolar depression and MDD. Furthermore, the available data seems not to allow judgements about its antipsychotic potential in comparison with currently prescribed antipsychotics.

Conclusions

Further studies should be carried out to better investigate its pharmacodynamic and clinical potential, particularly as alternative to current antipsychotic drugs.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EW445
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. s228
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.